Shots:

• The P-III study involves assessing Xywav vs PBO in patients aged ≥ 7yrs. with cataplexy or EDS with narcolepsy
• Results: study met its 1EPs & 2EPs i.e. differences in median change in a weekly number of cataplexy attacks and ESS scores. Results were published at World Sleep 2019
• Xywav is an oxybate product with a unique composition of cations resulting in 92% less sodium or ~1-000- 1-500 mg/night less than sodium oxybate at the recommended dosage range of 6-9gms. The company expects to launch in Q4’20- following RESM implementation

 ­ Ref: PRNewswire | Image: GMP News